CLEC12A and xeroderma pigmentosum: Murine splenicDCs targeted ex vivo with anti-Clec12a mAb-OVA fusions displayed superiorcross-presenting capabilities in comparison with Clec9a-targetingfusions as measured by proliferation of OT-I cells.144,145 Yet, in a head-to-head comparison of OVA protein fused to anti-Clec12amAb, anti-Clec9a mAb, or anti-DEC205 mAb, Clec12a-targeting fusionsinduced lower proliferation of CD8+ T cells in B6 micecompared to the latter two.109 This emphasizesthat in vitro studies of XP do not always accurately predict in vivoefficacy.